Current trends and healthcare resource usage in the hospital treatment of primary malignant brain tumor in Japan: A national survey using the diagnostic procedure combination database (J-ASPECT study-brain tumor)

Koji Yoshimoto, Akiko Kada, Daisuke Kuga, Ryusuke Hatae, Hideki Murata, Yojiro Akagi, Kunihiro Nishimura, Ryota Kurogi, Ataru Nishimura, Nobuhiro Hata, Masahiro Mizoguchi, Tetsuro Sayama, Koji Iihara

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We conducted this study to clarify the current trends and healthcare resource usage in the treatment of inpatients with primary malignant brain tumors. The Diagnostic Procedure Combination (DPC) data of all inpatients treated between 2013 and 2014 in the 370 core and branch hospitals enrolled in the Japanese Neurosurgical Society training program were collected. DPC is a discharge abstract and administrative claims database of inpatients. We assessed 6,142 primary, malignant brain tumor patients. Patient information, diagnostic information, treatment procedure, and healthcare resource usage were analyzed. Chemotherapy was the most frequent treatment (27% of cases), followed by surgery (13%) and surgery + chemo-radiotherapy (11%). Temozolomide (TMZ), the most frequently used chemotherapeutic drug, was administered to 1,236 patients. Concomitant TMZ and radiotherapy was administered to 816 patients, and was performed according to the Stupp regimen in many cases. The mean length of hospital stay (LOS) was 16 days, and the mean medical cost was 1,077,690 yen. The average medical cost of TMZ-only treatment was 1,138,620 yen whilst it was 4,424,300 yen in concomitant TMZ patients. The LOS was significantly shorter in high-volume than in low-volume hospitals, and the medical cost was higher in hospitals treating 21–50 patients compared to those treating 1–10 patients. However, the direct medical cost of TMZ treatment was the same across different volume hospitals. This is the first report of current trends and healthcare resource usage in the treatment of primary malignant brain tumor inpatients in the TMZ era in Japan.

Original languageEnglish
Pages (from-to)664-673
Number of pages10
JournalNeurologia medico-chirurgica
Volume56
Issue number11
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

temozolomide
Brain Neoplasms
Japan
Databases
Delivery of Health Care
Inpatients
Length of Stay
Therapeutics
Satellite Hospitals
Radiotherapy
Low-Volume Hospitals
Costs and Cost Analysis
Hospital Costs
Surveys and Questionnaires
Health Care Costs

All Science Journal Classification (ASJC) codes

  • Surgery
  • Clinical Neurology

Cite this

@article{9aa8c846de0147899560e8156b492ac9,
title = "Current trends and healthcare resource usage in the hospital treatment of primary malignant brain tumor in Japan: A national survey using the diagnostic procedure combination database (J-ASPECT study-brain tumor)",
abstract = "We conducted this study to clarify the current trends and healthcare resource usage in the treatment of inpatients with primary malignant brain tumors. The Diagnostic Procedure Combination (DPC) data of all inpatients treated between 2013 and 2014 in the 370 core and branch hospitals enrolled in the Japanese Neurosurgical Society training program were collected. DPC is a discharge abstract and administrative claims database of inpatients. We assessed 6,142 primary, malignant brain tumor patients. Patient information, diagnostic information, treatment procedure, and healthcare resource usage were analyzed. Chemotherapy was the most frequent treatment (27{\%} of cases), followed by surgery (13{\%}) and surgery + chemo-radiotherapy (11{\%}). Temozolomide (TMZ), the most frequently used chemotherapeutic drug, was administered to 1,236 patients. Concomitant TMZ and radiotherapy was administered to 816 patients, and was performed according to the Stupp regimen in many cases. The mean length of hospital stay (LOS) was 16 days, and the mean medical cost was 1,077,690 yen. The average medical cost of TMZ-only treatment was 1,138,620 yen whilst it was 4,424,300 yen in concomitant TMZ patients. The LOS was significantly shorter in high-volume than in low-volume hospitals, and the medical cost was higher in hospitals treating 21–50 patients compared to those treating 1–10 patients. However, the direct medical cost of TMZ treatment was the same across different volume hospitals. This is the first report of current trends and healthcare resource usage in the treatment of primary malignant brain tumor inpatients in the TMZ era in Japan.",
author = "Koji Yoshimoto and Akiko Kada and Daisuke Kuga and Ryusuke Hatae and Hideki Murata and Yojiro Akagi and Kunihiro Nishimura and Ryota Kurogi and Ataru Nishimura and Nobuhiro Hata and Masahiro Mizoguchi and Tetsuro Sayama and Koji Iihara",
year = "2016",
month = "1",
day = "1",
doi = "10.2176/nmc.oa.2016-0172",
language = "English",
volume = "56",
pages = "664--673",
journal = "Neurologia Medico-Chirurgica",
issn = "0470-8105",
publisher = "Japan Neurosurgical Society",
number = "11",

}

TY - JOUR

T1 - Current trends and healthcare resource usage in the hospital treatment of primary malignant brain tumor in Japan

T2 - A national survey using the diagnostic procedure combination database (J-ASPECT study-brain tumor)

AU - Yoshimoto, Koji

AU - Kada, Akiko

AU - Kuga, Daisuke

AU - Hatae, Ryusuke

AU - Murata, Hideki

AU - Akagi, Yojiro

AU - Nishimura, Kunihiro

AU - Kurogi, Ryota

AU - Nishimura, Ataru

AU - Hata, Nobuhiro

AU - Mizoguchi, Masahiro

AU - Sayama, Tetsuro

AU - Iihara, Koji

PY - 2016/1/1

Y1 - 2016/1/1

N2 - We conducted this study to clarify the current trends and healthcare resource usage in the treatment of inpatients with primary malignant brain tumors. The Diagnostic Procedure Combination (DPC) data of all inpatients treated between 2013 and 2014 in the 370 core and branch hospitals enrolled in the Japanese Neurosurgical Society training program were collected. DPC is a discharge abstract and administrative claims database of inpatients. We assessed 6,142 primary, malignant brain tumor patients. Patient information, diagnostic information, treatment procedure, and healthcare resource usage were analyzed. Chemotherapy was the most frequent treatment (27% of cases), followed by surgery (13%) and surgery + chemo-radiotherapy (11%). Temozolomide (TMZ), the most frequently used chemotherapeutic drug, was administered to 1,236 patients. Concomitant TMZ and radiotherapy was administered to 816 patients, and was performed according to the Stupp regimen in many cases. The mean length of hospital stay (LOS) was 16 days, and the mean medical cost was 1,077,690 yen. The average medical cost of TMZ-only treatment was 1,138,620 yen whilst it was 4,424,300 yen in concomitant TMZ patients. The LOS was significantly shorter in high-volume than in low-volume hospitals, and the medical cost was higher in hospitals treating 21–50 patients compared to those treating 1–10 patients. However, the direct medical cost of TMZ treatment was the same across different volume hospitals. This is the first report of current trends and healthcare resource usage in the treatment of primary malignant brain tumor inpatients in the TMZ era in Japan.

AB - We conducted this study to clarify the current trends and healthcare resource usage in the treatment of inpatients with primary malignant brain tumors. The Diagnostic Procedure Combination (DPC) data of all inpatients treated between 2013 and 2014 in the 370 core and branch hospitals enrolled in the Japanese Neurosurgical Society training program were collected. DPC is a discharge abstract and administrative claims database of inpatients. We assessed 6,142 primary, malignant brain tumor patients. Patient information, diagnostic information, treatment procedure, and healthcare resource usage were analyzed. Chemotherapy was the most frequent treatment (27% of cases), followed by surgery (13%) and surgery + chemo-radiotherapy (11%). Temozolomide (TMZ), the most frequently used chemotherapeutic drug, was administered to 1,236 patients. Concomitant TMZ and radiotherapy was administered to 816 patients, and was performed according to the Stupp regimen in many cases. The mean length of hospital stay (LOS) was 16 days, and the mean medical cost was 1,077,690 yen. The average medical cost of TMZ-only treatment was 1,138,620 yen whilst it was 4,424,300 yen in concomitant TMZ patients. The LOS was significantly shorter in high-volume than in low-volume hospitals, and the medical cost was higher in hospitals treating 21–50 patients compared to those treating 1–10 patients. However, the direct medical cost of TMZ treatment was the same across different volume hospitals. This is the first report of current trends and healthcare resource usage in the treatment of primary malignant brain tumor inpatients in the TMZ era in Japan.

UR - http://www.scopus.com/inward/record.url?scp=84995639913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995639913&partnerID=8YFLogxK

U2 - 10.2176/nmc.oa.2016-0172

DO - 10.2176/nmc.oa.2016-0172

M3 - Article

C2 - 27680329

AN - SCOPUS:84995639913

VL - 56

SP - 664

EP - 673

JO - Neurologia Medico-Chirurgica

JF - Neurologia Medico-Chirurgica

SN - 0470-8105

IS - 11

ER -